Blog Exposure - Zai Lab Inks Exclusive License Deal with Entasis for ETX2514 in the Asia/Pacific Region
Stock Monitor: Amgen Post Earnings Reporting
LONDON, UK / ACCESSWIRE / April 27, 2018 / Active-Investors.com has just released a free research report on Zai Lab Ltd (NASDAQ: ZLAB). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ZLAB as the Company's latest news hit the wire. On April 25, 2018, the Company announced that it has inked an exclusive license agreement with Entasis Therapeutics Holdings Inc. ("Entasis") for the rights to ETX2514, which is a novel broad-spectrum intravenous inhibitor of β-lactamases, in the Asia/Pacific region. Register today and get access to over 1000 Free Research Reports by joining our site below:
www.active-investors.com/registration-sg
Active-Investors.com is currently working on the research report for Amgen Inc. (NASDAQ: AMGN), which also belongs to the Healthcare sector as the Company Zai Lab. Do not miss out and become a member today for free to access this upcoming report at:
www.active-investors.com/registration-sg/?symbol=AMGN
Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Zai Lab most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:
www.active-investors.com/registration-sg/?symbol=ZLAB
Global Strategic Development Collaboration
The Companies also signed a global collaboration deal for the development of ETX2514SUL, a fixed-dose combination of ETX2514 and sulbactam, for the treatment of a variety of serious multidrug-resistant infections caused by Acinetobacter baumannii. Zai Lab will manage the portion of the Phase-3 trial of ETX2514SUL conducted in China. ETX2514SUL is currently in Phase-2 development with plans to move into global Phase-3 clinical trials in Q1 2019.
Acinetobacter baumannii is a Gram-negative bacterium causing severe infections associated with high mortality, and has emerged as a cause of numerous global outbreaks, displaying ever-increasing rates of antibiotic resistance which greatly limits treatment options.
Terms of the Agreement
Entasis has granted Zai Lab an exclusive license to develop and commercialize ETX2514SUL in specified countries in the Asia/Pacific region, including Japan.
Entasis and Zai Lab will cooperate in conducting Phase-3 trial in China, with Zai Lab taking the lead by conducting the screening, enrollment, and treatment of patients, and coordinating development and registration.
Entasis and Zai Lab can also partner on the development and commercialization of ETX2514 in combination with other active ingredients. A joint steering committee will be formed between the Companies to oversee development, regulatory, and commercialization activities in the Asia/Pacific territory.
In addition to the financial support for the portion of the Phase-3 trial conducted in China, Zai Lab will make an upfront payment of $5 million to Entasis, along with an aggregate of $7.6 million in near-term development milestones, and up to an aggregate of $91.0 million in additional milestone payments related to ETX2514SUL, plus royalties.
Collaboration to Offset Costs and Enable Patients Enrollment from China into Entasis' Global Phase-3 Clinical Trial
Manos Perros, Chief Executive Officer (CEO) of Entasis, stated that the Company is happy to partner with Zai Lab on the development and commercialization of ETX2514SUL in the Asia/Pacific region, most notably in Greater China, where the rate of Acinetobacter baumannii infections rank among the highest in the world. With their experienced leadership team, focus on innovation, and established expertise and network within the infectious diseases arena, Zai Lab is the ideal partner to help bring ETX2514SUL to the numerous patients in the region who need a new effective treatment option. Perros added that the collaboration will offset costs and enable enrollment of patients from China into Entasis' global Phase-3 clinical trial, further supporting its plans to rapidly progress ETX2514SUL to market.
Zai Lab's License Deal with Five Prime Therapeutics
In December 2017, Zai Lab signed an exclusive license deal with Five Prime Therapeutics, Inc. ("Five Prime") for FPA144 in Greater China, as well as a global strategic development collaboration. Five Prime's FPA144 is a first-in-class isoform-selective, humanized monoclonal antibody in clinical development as a targeted immuno-therapy for tumors that overexpress FGFR2b, including gastric and gastro-esophageal junction cancer. The Phase-3 portion of the FIGHT trial evaluating FPA144 plus chemotherapy is expected to start in H2 2018, and would serve as a global registrational study for the treatment of front-line gastric and gastro-esophageal junction cancers. Zai Lab will manage the Phase-3 portion of the trial in China.
About ETX2514
Entasis' ETX2514 is a broad-spectrum and potent inhibitor of class A, C, and D beta-lactamases. Sulbactam is a beta-lactam antimicrobial with activity against Acinetobacter baumannii, but beta-lactamase-mediated resistance to sulbactam is now widespread. In pre-clinical studies, ETX2514 restores sulbactam's antimicrobial activity. Entasis is developing the combination of sulbactam and ETX2514 for the treatment of drug-resistant Acinetobacter baumannii infections. A Phase-1 trial of ETX2514SUL has been recently completed with positive results for pharmacokinetics and drug toleration.
About Entasis Therapeutics Holdings Inc.
Entasis is a clinical-stage biopharmaceutical organization focused on the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. The Company was formed in 2015 and is based in Waltham, Massachusetts.
About Zai Lab Ltd
Established in 2014 and headquartered in Shanghai, China, Zai Lab is an innovative biopharmaceutical organization focused on bringing transformative medicines for cancer, autoimmune, and infectious diseases. The Company has offices in Beijing, manufacturing facilities at the Suzhou BioBay China Industry Park, and a satellite office in the US.
Stock Performance Snapshot
April 26, 2018 - At Thursday's closing bell, Zai Lab's stock slightly dropped 0.16%, ending the trading session at $18.41.
Volume traded for the day: 35.08 thousand shares.
After yesterday's close, Zai Lab's market cap was at $912.95 million.
The stock is part of the Healthcare sector, categorized under the Biotechnology industry. This sector was up 1.2% at the end of the session.
Active-Investors:
Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
A-I has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: info@active-investors.com
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Active-Investors
